John Simard - 17 Mar 2025 Form 4 Insider Report for XBiotech Inc. (XBIT)

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: XBIT
Reported as of: 17 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Mar 2025, 15:03:42 UTC
Prior SEC filing: 04 Feb 2025
Source filing: View source filing
Reporting owner signature: John Simard

Key filing fact

John Simard filed Form 4 for XBiotech Inc. (XBIT) on 19 Mar 2025.

Key facts

This page summarizes John Simard's Form 4 filing for XBiotech Inc. (XBIT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Mar 2025, 15:03.

Change

Previous filing in this sequence was filed on 04 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001639078 Primary reporting owner

SIMARD JOHN

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: 5217 WINNEBAGO LANE, AUSTIN
Signature: John Simard
Signature date: 19 Mar 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XBIT transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +1,026,228
Change %: +118%
Price: $0.000000
Shares after: 1,896,609
Date: 17 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,026,228
Exercise price: $3.52
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On March 17, 2025 (the Grant Date) John Simard was granted nonstatutory stock options under the Company's 2015 Equity Incentive Plan to purchase shares of the Company's Common Stock at an exercise price equal to the closing price of the Company's common stock, as reported by the Nasdaq Stock Market, on the Grant Date. The options vested immediately on the Grant Date.